Nyrada – Cholesterol-Lowering Program Update

• Cholesterol-Lowering Program preclinical safety and toxicology studies remain on track to commence Q3 CY2022
• COVID-related lockdowns in Shanghai delay drug manufacture, Phase I now expected to commence 1H CY2023
• European Patent Office formally grants patent for novel compounds inhibiting PCSK9